EP0999757A1 - Nutritional composition for subjects under stress - Google Patents
Nutritional composition for subjects under stressInfo
- Publication number
- EP0999757A1 EP0999757A1 EP98929576A EP98929576A EP0999757A1 EP 0999757 A1 EP0999757 A1 EP 0999757A1 EP 98929576 A EP98929576 A EP 98929576A EP 98929576 A EP98929576 A EP 98929576A EP 0999757 A1 EP0999757 A1 EP 0999757A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- carnitine
- stress
- alkanoyl
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 235000016709 nutrition Nutrition 0.000 title abstract description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 14
- 240000003444 Paullinia cupana Species 0.000 claims abstract description 10
- 235000000556 Paullinia cupana Nutrition 0.000 claims abstract description 10
- -1 alkanoyl L-carnitine Chemical compound 0.000 claims abstract description 10
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 8
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000011090 malic acid Nutrition 0.000 claims abstract description 8
- 239000001630 malic acid Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims abstract description 8
- 229960000317 yohimbine Drugs 0.000 claims abstract description 8
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 7
- 244000068988 Glycine max Species 0.000 claims abstract description 7
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 7
- 239000000787 lecithin Substances 0.000 claims abstract description 7
- 229940067606 lecithin Drugs 0.000 claims abstract description 7
- 235000010445 lecithin Nutrition 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 239000000419 plant extract Substances 0.000 claims abstract 3
- 240000004371 Panax ginseng Species 0.000 claims description 11
- 235000008434 ginseng Nutrition 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 9
- 240000000143 Turnera diffusa Species 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 235000004952 turnera diffusa Nutrition 0.000 claims description 9
- 201000001881 impotence Diseases 0.000 claims description 4
- 206010025482 malaise Diseases 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 241000682653 Corynanthe Species 0.000 claims description 2
- 235000002789 Panax ginseng Nutrition 0.000 claims description 2
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 206010003549 asthenia Diseases 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000001107 psychogenic effect Effects 0.000 claims description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 2
- 241000190079 Turnera Species 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- 241000675108 Citrus tangerina Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229940071325 yohimbine 5 mg Drugs 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000010242 Paullinia Nutrition 0.000 description 1
- 241001119526 Paullinia Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000009206 Turnera diffusa Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a nutritional composition or medical food for subjects in a debilitated state as a result of stress.
- This syndrome afflicts all social classes, but mainly affects people involved in the production cycle, who often, as a result, are subject to greater competitive stress stimuli both in the work environment and in the conduct of their social relations.
- stress syndrome is not a debilitating "disease” to the extent that it makes people bed-ridden, but it is certainly a frequent cause of people taking days off work. Since it afflicts a substantial number of individuals, it causes a considerable burden of economic damage to the entire community during the working year. Stress syndrome, which in the past was improperly called "nervous breakdown', is characterised, in the absence of active disease, by concomitant states of malaise, such as a lack of strength, debilitation, states of mental and physical fatigue, lack of concentration and attention, and lack of sexual vigour and libido.
- Benzodiazepines are used to alleviate symptoms such as anxiety or irritability, but present the drawback of causing addiction as well as further depressing libido and sexual vigour, thus triggering a mechanism in male subjects of reproductive age which itself proves to be a cause of additional malaise.
- L-carnitine when used for the treatment of patients undergoing regular dialysis treatment, also induces recovery of normal sexual function in such patients (De Felice SL, Lyons P, Gaf ⁇ ar MC, Sheridan MJ, Dial-Transplant, 1996, vol/iss/pg. 25/6 368-373).
- Ginseng has been used in Chinese medicine for more than 2000 years for the treatment of sexual impotence and for other diseases. Also well known is the activity of yohimbine in improving sexual function; see, for example, "Clinical Studies in Impotence”: K Reid et al., Lancet 2, 421-423 (1987). Guarana is used by Brazilian indigenous populations for the preparation of a stimulating beverage (Pharmacognosy, Edward P Claus, Varro E Tyler, Lynn R Brady, 6th edition pp. 292-293). Damiana has also long been known to be endowed, according to popular belief, with stimulant activity (J Psychoactive Drugs 16 (3): 267-268, 1984).
- the purpose of the present invention is now to provide a therapeutic medical food suitable for alleviating and treating states of malaise caused by stress and for promoting sexual vigour.
- the therapeutic medical food of the invention comprises the following compounds in combination:
- ginseng natural extract of Panax ginseng
- yohimbine natural extract of Corynanthe yohimbe
- damiana natural extract of Turnera diffusa, ⁇ ar. aphrodisiaca
- the alkanoyl L-carnitine should preferably be chosen from among the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts.
- pharmacologically acceptable salt of L- camitine or of an alkanoyl L-carnitine is any salt of these with an acid which does not give rise to unwanted toxic or side effects.
- acids are well known to pharmacologists and experts in pharmacy.
- Non-limiting examples of pharmacologically acceptable salts of L-carnitine or of the alkanoyl L-carnitines are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
- the components of the combination according to the invention exhibit an unexpected potent synergistic effect which brings about an improvement in physical performance and in the mental and physical condition of patients suffering from stress syndrome.
- Very important and surprising is the synergistic effect shown by the combination of ginseng, yohimbine and L-carnitine in restoring sexual vigour and libido,
- the effect of the combination is, in fact, distinctly superior to the sum of the effects of the individual components.
- L-carnitine and lecithin of soya favour the metabolisation of fatty acids, exerting a hypolipaemic effect on the body, which, though having no direct repercussions in terms of improving stress syndrome, is aimed at enhancing the individual's general state of health.
- the weight-to-weight ratio of L-carnitine or of an alkanoyl L- carnitine to ginseng, yohimbine, guarana and damiana may vary over a broad range, This ratio should preferably range from 1:0.1:0.0025:0.1:0.1 to 1 : 10:0.25: 100:100.
- One preferred ratio is
- composition according to the invention may additionally contain vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM970435 | 1997-07-16 | ||
| IT97RM000435A IT1293539B1 (it) | 1997-07-16 | 1997-07-16 | Composizione nutritiva per soggetti in stato di debilitazione causato da stress |
| PCT/IB1998/001056 WO1999003364A1 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0999757A1 true EP0999757A1 (en) | 2000-05-17 |
Family
ID=11405180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98929576A Withdrawn EP0999757A1 (en) | 1997-07-16 | 1998-07-10 | Nutritional composition for subjects under stress |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0999757A1 (ja) |
| JP (1) | JP2001510026A (ja) |
| KR (1) | KR20010021694A (ja) |
| CN (1) | CN1263439A (ja) |
| AU (1) | AU727448B2 (ja) |
| CA (1) | CA2296540A1 (ja) |
| HU (1) | HUP0004526A3 (ja) |
| IT (1) | IT1293539B1 (ja) |
| PL (1) | PL338079A1 (ja) |
| SK (1) | SK181999A3 (ja) |
| WO (1) | WO1999003364A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410277B (de) * | 2001-02-22 | 2003-03-25 | Peter Dr Frigo | Getränk |
| LV12978B (en) * | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
| ITRM20010708A1 (it) | 2001-12-04 | 2003-06-04 | Sigma Tau Ind Farmaceuti | Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. |
| JP2006503844A (ja) * | 2002-09-28 | 2006-02-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐａｎａｘｇｉｎｓｅｎｇ及びＰａｕｌｌｉｎｉａｃｕｐａｎａ抽出物を含有する組成物 |
| DE102005053241A1 (de) * | 2005-11-08 | 2007-05-16 | Schwabe Willmar Gmbh & Co | Extrakte aus der Rinde von Corynanthe-Arten und deren Verwendung sowie diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen |
| WO2009066712A1 (ja) * | 2007-11-21 | 2009-05-28 | Kracie Pharma, Ltd. | アロマターゼ阻害剤 |
| JP6446265B2 (ja) * | 2014-12-26 | 2018-12-26 | 花王株式会社 | 固形状組成物 |
| CN113116898A (zh) * | 2021-04-20 | 2021-07-16 | 北京天玺宝科技有限公司 | 一种具有减肥功能的包含左卡尼汀或乙酰左卡尼汀和育亨宾的组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| FR2748659B1 (fr) * | 1996-05-14 | 1998-07-24 | Lvmh Rech | Composition topique amincissante |
| US5744187A (en) * | 1996-12-16 | 1998-04-28 | Gaynor; Mitchel L. | Nutritional powder composition |
-
1997
- 1997-07-16 IT IT97RM000435A patent/IT1293539B1/it active IP Right Grant
-
1998
- 1998-07-10 WO PCT/IB1998/001056 patent/WO1999003364A1/en not_active Application Discontinuation
- 1998-07-10 KR KR1020007000253A patent/KR20010021694A/ko not_active Application Discontinuation
- 1998-07-10 JP JP2000502680A patent/JP2001510026A/ja active Pending
- 1998-07-10 PL PL98338079A patent/PL338079A1/xx unknown
- 1998-07-10 AU AU79277/98A patent/AU727448B2/en not_active Ceased
- 1998-07-10 SK SK1819-99A patent/SK181999A3/sk unknown
- 1998-07-10 EP EP98929576A patent/EP0999757A1/en not_active Withdrawn
- 1998-07-10 HU HU0004526A patent/HUP0004526A3/hu unknown
- 1998-07-10 CA CA002296540A patent/CA2296540A1/en not_active Abandoned
- 1998-07-10 CN CN98807193A patent/CN1263439A/zh active Pending
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9903364A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2296540A1 (en) | 1999-01-28 |
| JP2001510026A (ja) | 2001-07-31 |
| PL338079A1 (en) | 2000-09-25 |
| ITRM970435A0 (ja) | 1997-07-16 |
| CN1263439A (zh) | 2000-08-16 |
| SK181999A3 (en) | 2000-10-09 |
| AU7927798A (en) | 1999-02-10 |
| WO1999003364A1 (en) | 1999-01-28 |
| ITRM970435A1 (it) | 1999-01-16 |
| AU727448B2 (en) | 2000-12-14 |
| HUP0004526A2 (hu) | 2001-04-28 |
| KR20010021694A (ko) | 2001-03-15 |
| IT1293539B1 (it) | 1999-03-01 |
| HUP0004526A3 (en) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6831103B1 (en) | Composition comprising theanine | |
| KR100680121B1 (ko) | (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제 | |
| US7674482B2 (en) | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods | |
| US5324516A (en) | Galenic composition for decreasing blood alcohol concentration | |
| GB2596849A (en) | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual | |
| JP7461066B2 (ja) | スポーツ上の動作を強化するための組成物 | |
| JP5275251B2 (ja) | 肝臓疾患を予防及び処置するための組合せ薬草の抽出物を含む組成物 | |
| KR100481188B1 (ko) | 글루타민산염관련질환치료용알카노일-l-카르니틴의용도 | |
| AU727448B2 (en) | Nutritional composition for subjects under stress | |
| US5482712A (en) | Galenic composition | |
| US20040213829A1 (en) | Dietary supplement | |
| KR20050033505A (ko) | 주의력 결핍 증후군 치료에 있어서 포스파티딜세린의 사용 | |
| US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
| JP2007500755A (ja) | 月経前症候群の症状を抑える方法 | |
| US11376294B2 (en) | Mangiferin-containing compositions for improving sports performance | |
| US20030194453A1 (en) | Dietary supplement | |
| WO2002078616A2 (en) | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid | |
| AU2002305132A1 (en) | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid | |
| MXPA00000442A (en) | Nutritional composition for subjects under stress | |
| KR20090024215A (ko) | 인간의 성적 활동성을 향상시키기 위한 수단과 방법들 | |
| CZ200088A3 (cs) | Nutriční přípravek pro stresované subjekty | |
| EP1383579A2 (en) | Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder | |
| KR20230106783A (ko) | 초임계유체 추출법을 이용한 혼합추출물을 유효성분으로 함유하는 남성 성기능 개선용 조성물 | |
| Soldati | Ginseng, Asian (Panax ginseng) | |
| WO2008152624A2 (en) | Herbal energy-enhancing formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19991227 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL PAYMENT 19991227;LT PAYMENT 19991227;LV PAYMENT 19991227;MK PAYMENT 19991227;RO PAYMENT 19991227;SI PAYMENT 19991227 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Withdrawal date: 20011016 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1028525 Country of ref document: HK |